RCH Solutions, Inc, a leading provider of Bio-IT expertise exclusively for the Life Sciences, announces the introduction of new, cutting-edge AI services to revolutionize drug discovery and development. One of the first to embrace this industry paradigm shift toward AI and machine learning, the new AI services from RCH unlock never-before-tapped opportunities for increased efficiency, precision, and innovation for biotechs and pharmaceutical companies.
“It’s undeniable that AI powers efficiency gains, cost optimization, and more advanced data management than ever before. But the transformative potential of AI in drug development extends beyond these surface-level improvements,” said Michael Riener, CEO of RCH Solutions. “While Platform and ML Ops have been a consistent service delivered for several years, moving into the discriminative and generative landscape is where things really start to get exciting.”
Currently, the team is helping several prominent Life Sciences companies navigate unique and complex AI projects, including the integration of Generative AI for better vaccine development and delivery.
In addition to providing full-stack bio-IT support, RCH’s expanded AI-specific services include:
- Platform Ops for AI / ML Ops – Tailored infrastructure, technologies, and support to facilitate a collaborative and efficient environment for AI-enabled scientific computing
- Discriminative AI – Through advanced GPUs, software expertise, and leading technologies, RCH will build and implement conditional models that lead to deeper, more robust data analysis and faster, more insightful decision-making
- Generative AI – Leveraging Large Language Models, these services enable teams to train and prompt custom generative models, creating new and advanced assumptions and data for analysis and processing
Also Read: BenevolentAI Appoints New Chief Technology Officer
“AI has an incredible capacity to analyze robust datasets, identify patterns, and predict outcomes, which translates to more effective predictive modeling, target identification, molecular design, clinical trial optimization and more,” said Phil Eschallier, CTO. “This increased accuracy and speed gives companies a competitive edge in making more rapid decisions and bringing treatments to market faster than ever. But it’s important to note—AI is still just one of the many tools in the tool box. It’s important for organizations to know when and how to use it best to see the most success.”
To help companies know exactly where to begin or advance their AI journey, RCH rolled out a comprehensive, five-step strategic process—from data collection to optimization monitoring and continuous improvement—tailored to each customers’ unique IT infrastructure, use case, challenges, and scientific goals.
“AI has the power to revolutionize global healthcare by making treatments more accessible, affordable, and tailored to diverse patient populations,” shared Riener. “The companies that embrace AI as a standard component of their operations are well-positioned to make the biggest impact, and RCH is committed to seeing AI through its many transformations ahead and helping Life Sciences customers navigate this journey from adoption to optimization.”
SOURCE: PRWeb